GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CellaVision AB (OTCPK:CLVSF) » Definitions » Cyclically Adjusted PS Ratio

CellaVision AB (CellaVision AB) Cyclically Adjusted PS Ratio : 10.60 (As of May. 01, 2024)


View and export this data going back to 2010. Start your Free Trial

What is CellaVision AB Cyclically Adjusted PS Ratio?

As of today (2024-05-01), CellaVision AB's current share price is $20.24. CellaVision AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $1.91. CellaVision AB's Cyclically Adjusted PS Ratio for today is 10.60.

The historical rank and industry rank for CellaVision AB's Cyclically Adjusted PS Ratio or its related term are showing as below:

CLVSF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 6.14   Med: 23.42   Max: 37.78
Current: 10.65

During the past years, CellaVision AB's highest Cyclically Adjusted PS Ratio was 37.78. The lowest was 6.14. And the median was 23.42.

CLVSF's Cyclically Adjusted PS Ratio is ranked worse than
88.27% of 469 companies
in the Medical Devices & Instruments industry
Industry Median: 2.12 vs CLVSF: 10.65

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

CellaVision AB's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.685. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.91 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


CellaVision AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for CellaVision AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellaVision AB Cyclically Adjusted PS Ratio Chart

CellaVision AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.03 24.69 22.27 12.49 10.15

CellaVision AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.82 9.32 7.57 10.15 11.19

Competitive Comparison of CellaVision AB's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, CellaVision AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellaVision AB's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where CellaVision AB's Cyclically Adjusted PS Ratio falls into.



CellaVision AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

CellaVision AB's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=20.24/1.91
=10.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellaVision AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, CellaVision AB's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.685/130.9575*130.9575
=0.685

Current CPI (Mar. 2024) = 130.9575.

CellaVision AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.340 100.432 0.443
201409 0.277 100.161 0.362
201412 0.398 100.225 0.520
201503 0.254 99.950 0.333
201506 0.261 99.995 0.342
201509 0.374 100.228 0.489
201512 0.304 100.276 0.397
201603 0.293 100.751 0.381
201606 0.332 101.019 0.430
201609 0.336 101.138 0.435
201612 0.331 102.022 0.425
201703 0.438 102.022 0.562
201706 0.380 102.752 0.484
201709 0.321 103.279 0.407
201712 0.380 103.793 0.479
201803 0.395 103.962 0.498
201806 0.438 104.875 0.547
201809 0.396 105.679 0.491
201812 0.515 105.912 0.637
201903 0.469 105.886 0.580
201906 0.501 106.742 0.615
201909 0.413 107.214 0.504
201912 0.666 107.766 0.809
202003 0.573 106.563 0.704
202006 0.532 107.498 0.648
202009 0.417 107.635 0.507
202012 0.657 108.296 0.794
202103 0.657 108.360 0.794
202106 0.676 108.928 0.813
202109 0.640 110.338 0.760
202112 0.757 112.486 0.881
202203 0.712 114.825 0.812
202206 0.767 118.384 0.848
202209 0.542 122.296 0.580
202212 0.615 126.365 0.637
202303 0.557 127.042 0.574
202306 0.661 129.407 0.669
202309 0.635 130.224 0.639
202312 0.820 130.958 0.820
202403 0.685 130.958 0.685

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CellaVision AB  (OTCPK:CLVSF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


CellaVision AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of CellaVision AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CellaVision AB (CellaVision AB) Business Description

Traded in Other Exchanges
Address
Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers.

CellaVision AB (CellaVision AB) Headlines

From GuruFocus

3 Scandinavian Companies With Strong Margin Growth

By James Li James Li 12-01-2020